Iterum Therapeutics Plc (ITRM) Misses Q3 EPS by 5c

Iterum Therapeutics Plc (NASDAQ: ITRM) reported Q3 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $390 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Iterum Therapeutics Plc (ITRM) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Instagram expands TV app to Samsung devices, tests new features
• Robinhood (HOOD) call put ratio 4 calls to 1 put with a focus on 2500 contracts of August 160 calls